<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VECURONIUM</span><br/>(vek-yoo-roe'nee-um)<br/><span class="topboxtradename">Norcuron<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">nondepolarizing skeletal muscle relaxant</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Intermediate-acting nondepolarizing skeletal muscle relaxant structurally similar to pancuronium. Demonstrates negligible
         histamine release and therefore has minimal direct effect on cardiovascular system, unlike older neuromuscular blocking agents.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits neuromuscular transmission by competitively binding with acetylcholine to motor endplate receptors (common also with
         other drugs of this class). Results in skeletal muscular relaxation. Given <small>ONLY</small> after induction of general anesthesia.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct for general anesthesia to produce skeletal muscle relaxation during surgery. Especially useful for patients with severe
         kidney disease, limited cardiac reserve, and history of asthma or allergy. Also to facilitate endotracheal intubation.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Continuous infusion for facilitation of mechanical ventilation.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safe use during pregnancy (category C), lactation, is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe liver disease; impaired acidbase, fluid and electrolyte balance; severe obesity; adrenal or neuromuscular disease
         (myasthenia gravis, Eaton-Lambert syndrome); patients with slow circulation time (cardiovascular disease, old age, edematous
         states); malignant hyperthermia.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Skeletal Muscle Relaxation</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i><img src="../images/special/greaterorequal.gif"/>1 y</i>, 0.040.1 mg/kg initially, then after 2540 min, 0.010.15 mg/kg q1215 min or 0.001 mg/kg/min by continuous
               infusion<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 0.1 mg/kg, followed by 0.030.15 mg/kg q12h prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Vecuronium is administered only by qualified clinicians.
         		
      </p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 1020 mg with 50 mL sterile water for injection (supplied).  <span class="methodtype">Continuous:</span> Further dilute with up to 100 mL D5W, NS, or RL to yield 0.10.2 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a bolus dose over 30 sec.  <span class="methodtype">Continuous:</span> Give at the required rate.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>diazepam,</b>
<b>etomidate,</b>
<b>furosemide,</b>
<b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate after reconstitution below 30° C (86° F), unless otherwise directed. Discard solution after 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Skeletal muscle weakness, <span class="speceff-life">malignant hyperthermia</span>. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory depression</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">general anesthetics</span> increase neuromuscular blockade and duration of action; <span class="classification">aminoglycosides</span>, <b>bacitracin,</b>
<b>polymyxin B,</b>
<b>clindamycin,</b>
<b>lidocaine,</b>
<b>parenteral magnesium,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>trimethaphan,</b>
<b>verapamil</b> increase neuromuscular blockade; <span class="classification">diuretics</span> may increase or decrease neuromuscular blockade; <b>lithium</b> prolongs duration of neuromuscular blockade; <span class="classification">narcotic analgesics</span> increase possibility of additive respiratory depression; <b>succinylcholine</b> increases onset and depth of neuromuscular blockade; <b>phenytoin</b> may cause resistance to or reversal of neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  Peak: 35 min. <span class="typehead">Duration:</span> 2540 min. <span class="typehead">Distribution:</span> Well distributed to tissues and extracellular fluids; crosses placenta; distribution into breast milk unknown. <span class="typehead">Metabolism:</span> Rapid nonenzymatic degradation in bloodstream. <span class="typehead">Elimination:</span> 3035% excreted in urine, 3035% in bile. <span class="typehead">Half-Life:</span> 3080 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline serum electrolytes, acidbase balance, and kidney &amp; liver functions.</li>
<li>Use peripheral nerve stimulator during and following drug administration to avoid risk of overdosage and to identify residual
            paralysis during recovery period. This is especially indicated when cautious use of drug is specified.
         </li>
<li>Monitor vital signs at least q15 min until stable, then every 30 min for the next 2 h. Also monitor airway patency until assured
            that patient has fully recovered from drug effects. Note rate, depth, and pattern of respirations. Obese patients and patients
            with myasthenia gravis or other neuromuscular disease may have ventilation problems.
         </li>
<li>Evaluate patients for recovery from neuromuscular blocking (curare-like) effects as evidenced by ability to breathe naturally
            or take deep breaths and cough, to keep eyes open, and to lift head keeping mouth closed and by adequacy of hand grip strength.
            Notify physician if recovery is delayed.
         </li>
<li>
            							Note: Recovery time may be delayed in patients with cardiovascular disease, edematous states, and in older adults.
            						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>